BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
17 déc. 2020 08h30 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that...
Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease
27 nov. 2015 06h00 HE
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...
Mesoblast Investor Update
23 nov. 2015 00h07 HE
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 23, 2015 (GLOBE NEWSWIRE) -- The Mesoblast Board and management are committed to delivering the Tier 1 product milestones as set out in the recent F-1...
Mesoblast Lists On Nasdaq
15 nov. 2015 18h46 HE
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Nov. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol...
Mesoblast Chairman's Address to 2015 Annual General Meeting
22 oct. 2015 02h00 HE
|
Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting.
This has been another exciting and productive year in the history of our...
Full Product Approval In Japan Received By Mesoblast Licensee
18 sept. 2015 01h23 HE
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
16 août 2015 20h28 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
Type 2 Diabetes Trial Results Published In Diabetes Care
22 juil. 2015 19h17 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
18 mai 2015 05h39 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment...